10.08
+0.30%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Harbin Medisan Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002900.SZ. It has been listed since 22 September 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥789.4m and a net loss of CN¥339.6m. At that date it held total assets of CN¥3.46bn and shareholders' equity of CN¥1.77bn.
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical medicine preparations. The company is headquartered in Harbin, Heilongjiang. The company went IPO on 2017-09-22. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The firm's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The firm mainly distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Sept 2017
- Employees
- 1,721
- Website
- medisan.com.cn ↗
Leadership
Pay as last reported
- Mr. Jianfei QinChairman of the Board, President, since 2023CN¥750,000
- Mr. Guomin ZhugeVice Chairman of the Board, since 2013CN¥600,000
- Mr. Zhicheng ZhaoChief Financial OfficerCN¥340,000
- Mr. Yanfei LiangVice President, Secretary of the Board, DirectorCN¥560,000
- Mr. Qingfu ZhaoDeputy General Manager, Director, since 2013CN¥520,000
- Mr. Qingji FanDeputy General Manager, since 2019CN¥480,000
- Ms. Bing HanDeputy General ManagerCN¥480,000
- Mr. Jiantao QinDirectorCN¥250,000
- Ms. Li ZhouDirectorCN¥120,000
- Mr. Zihong ZhuDirector
- Mr. Hongquan LiuIndependent Director
- Mr. Dong WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Harbin Medisan employs 1,721 full-time employees in the Health Care sector.
- The company's products cover nervous system and cardio-cerebrovascular therapeutic fields.
- Harbin Medisan produces freeze-dried powder injections and large infusion products domestically.
Weaknesses
- Harbin Medisan's products are limited to domestic market distribution within China.
- The company has no international presence or global market expansion plans.
- Harbin Medisan's business is focused solely on chemical medicine preparations.
Opportunities
- Expanding into the musculoskeletal therapeutic field for new product development.
- Increasing market share in the systemic anti-infection therapeutic segment.
- Growing demand for nutritional infusion products in the domestic market.
Threats
- Competition from other Chinese pharmaceutical companies in the domestic market.
- Regulatory changes affecting the pharmaceutical industry in China.
- Economic downturns impacting domestic healthcare spending in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.